Reading COO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track COO free→Reading COO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track COO free→NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-06-12
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, but management's recent track record has been unsteady, with frequent disruptive corporate changes. Earnings quality is robust, and risk is moderate, while the sector backdrop is a headwind. Peer multiples imply a price about 11% above where it trades (it looks cheap on this basis); the read is fair, quality intact. The outlook hinges on guidance changes and sector trends, particularly the performance of key Healthcare bellwethers. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 8 valuation methods, at three horizons. Current price $67.88. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $68 COO trades at 20× p/e, in line with its 20× p/e peer median. Our $76 fair value reflects that, high confidence. Analysts: $61–$86. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 10% below a flat-multiple fair value, below our forecast of about 7%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 4.04x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 60% of the time over the next year (vs 48% for the rest of the cohort, n=1703).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $1.19 → $1.12 (-5.9% / 30d). 0 raised, 14 cut, 15 covering analysts.
0 upgrades, 0 downgrades / 30d, 9 maintained. 63% of analysts rate Buy.
5 PT revisions / 30d. Avg target 25.0% above current price.
0 positive, 2 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Met or beat guidance 67% of the last 3 guided quarters · 69.6% avg surprise
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$107.
How much price usually moves either way.
On a bad day, this stock has moved -$253.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,005.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-12
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: This is the threshold for organic growth guidance. Falling below it may signal weakening demand.
Confirms:Q3 organic revenue growth was below 4.5%.
Disproves:Q3 organic revenue growth reported at or above 4.5%.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for COO yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On June 4, 2026, The Cooper Companies, Inc. (the “Company”) issued a press release reporting results for its fiscal second quarter ended April 30, 2026. A copy of this release is attached and incorporated by reference. This information, including the exhibits(s) hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing unde…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$61.00 – $86.00 (median $85.00) · 5 analysts · as of 2026-06-05
Roughly priced in line with peers.
Cheaper than its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
A side-by-side read on sector standing, valuation, and risk versus Health Care Supplies.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
COO Cooper Companies (The) | Above typical Show detailsSector percentile: 71 of 100 | fair | moderate |
MDLN MEDLINE INC | — | full | moderate |
WST West Pharmaceutical Services | Above typical Show detailsSector percentile: 93 of 100 | expensive | moderate |
ALGN Align Technology | Above typical Show detailsSector percentile: 94 of 100 | fair | elevated |
LNTH Lantheus Holdings | Above typical Show detailsSector percentile: 84 of 100 | full | elevated |
5 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
Not investment advice. As of 2026-06-12.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-12.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on sustainable, profitable growth and strong cash flow while maintaining discipline in a dynamic operating environment.
Continue to enhance operating margins through disciplined execution and meaningful synergies from reorganization.
Aim to increase free cash flow to $600-$625 million in fiscal year 2026.
Continue the share repurchase program as a core element of capital allocation strategy.
Why it matters: Higher margins show good execution and cost control.
Confirms:Operating margin was above 27% in Q2.
Disproves:Operating margin reported at or below 27% for Q2.
Why it matters: Updates may show confidence in cash flow and spending plans.
Confirms:They announced more share buybacks beyond the current $873.9 million.
Disproves:No updates or reductions in the share repurchase program.
Why it matters: Higher charges may hurt profits and cash flow. This could lower investor confidence.
Confirms:Charges from lawsuits were above $300 million.
Disproves:Charges from lawsuits were below $300 million.
Why it matters: His experience may improve strategy and operations. This could help long-term value.
Confirms:People liked the board after Keel was appointed.
Disproves:There was negative feedback or issues with board decisions after the appointment.
Why it matters: Keeping this guidance shows strong cash flow. This helps growth and share buybacks.
Confirms:Free cash flow guidance confirmed at $600-$625 million.
Disproves:Free cash flow guidance revised down from $600-$625 million.
Other Events. As described in its June 4, 2026 press release, the Company recorded a charge as further described below. In December 2023, CooperSurgical, one of the Company’s two business units, initiated a voluntary recall of three specific lots of CooperSurgical’s LifeGlobal TM global ® embryo culture media that it had produced. Subsequently, claims and lawsuits in various U.S. and international jurisdictions were brought by individuals who generally allege that they suffered damages associ…
Director — Paul Keel: The company appointed Paul Keel as a new director.
Results of Operations and Financial Condition. On March 5, 2026, The Cooper Companies, Inc. issued a press release reporting results for its fiscal first quarter ended January 31, 2026. A copy of this release is attached and incorporated by reference. This information, including the exhibits(s) hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securiti…
Entry into a Material Definitive Agreement. Amendment No. 3 to Term Loan Agreement On February 3, 2026, The Cooper Companies, Inc. (the “Company”) entered into Amendment No. 3 to Term Loan Agreement (the “Third Amendment to 2021 Loan Agreement”), among the Company, as the borrower, the subsidiary guarantors party thereto, the lenders party thereto and PNC Bank, National Association (“PNC”), as administrative agent, to amend the Term Loan Agreement, dated as of December 17, 2021 (as previously…